Tiagabine
- Generic Name
- Tiagabine
- Brand Names
- Gabitril
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25NO2S2
- CAS Number
- 115103-54-3
- Unique Ingredient Identifier
- Z80I64HMNP
- Background
Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
- Indication
For the treatment of partial seizures
- Associated Conditions
- Partial-Onset Seizures
- Associated Therapies
- -
Population Pharmacokinetics of Antiepileptic in Pediatrics
- Conditions
- Interventions
- Biological: Valproic acidBiological: carbamazepineBiological: phenobarbitalBiological: phenytoinBiological: levetiracetamBiological: lamotrigineBiological: topiramateBiological: oxcarbazepineBiological: stiripentolBiological: clobazamBiological: brivaracétamBiological: felbamateBiological: lacosamideBiological: rufinamideBiological: gabapentineBiological: pregabalineBiological: sultiameBiological: tiagabineBiological: vigabatrineBiological: mesuximideBiological: primidoneBiological: perampanelBiological: ethosuximideBiological: zonisamideBiological: cannabidiolOther: genetic polymorphisms
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1000
- Registration Number
- NCT03196466
- Locations
- 🇫🇷
AP-HP Cochin, Paris, France
Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT02387710
- Locations
- 🇺🇸
Sleep Disorders Research Program Brigham and Women's Hospital, Boston, Massachusetts, United States
Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Rajesh Narendran
- Target Recruit Count
- 11
- Registration Number
- NCT01904487
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 440
- Registration Number
- NCT00236067
- Locations
- 🇺🇸
Neurobehavioral Research, Inc., Lawrence, New York, United States
🇺🇸CNS Research Institute, Clementon, New Jersey, United States
🇺🇸Social Psychiatry Research Inst., New York, New York, United States
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 440
- Registration Number
- NCT00236054
- Locations
- 🇺🇸
Cunningham Clinical Research, LLC, Edwardsville, Illinois, United States
🇺🇸Health Quest Clinical Trials, San Diego, California, United States
🇺🇸Janus Center for Psychiatric Research, West Palm Beach, Florida, United States
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 880
- Registration Number
- NCT00236015
- Locations
- 🇺🇸
Pharmacology Research Institute, Riverside, California, United States
🇺🇸Medark Clinical Trials and Research, Morganton, North Carolina, United States
🇺🇸Richard Weisler, MD and Associates, Raleigh, North Carolina, United States
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Registration Number
- NCT00214994
- Locations
- 🇺🇸
CNS Research Institute, Clementon, New Jersey, United States
🇺🇸University of Florida, Jacksonville, Florida, United States
🇺🇸LSUHSC in Shreveport, Shreveport, Louisiana, United States
Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT00208741
- Locations
- 🇺🇸
Columbia/New York State Psychiatric Institute, New York, New York, United States
🇺🇸Hillside Hospital of the North Shore-Long Island Jewish Health System, Long Island, New York, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
Treating Schizophrenia by Correcting Abnormal Brain Development
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT00179465
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1
- First Posted Date
- 2005-08-11
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Target Recruit Count
- 80
- Registration Number
- NCT00129298
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.